Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella’s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella’s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Copyright West LLC. Minimum 15 minutes delayed.
Announced positive interim findings from ongoing clinical study of AXA1125 and AXA1957; expect to report top-line data in second quarter of 2020 Completed enrollment in ongoing clinical study of AXA1665; expect to report top-line data in third quarter of 2020 Bolstered intellectual property
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it will give an oral presentation at
60 subjects enrolled in AXA1665-002 Top-line data expected in mid-2020 IND submission for overt hepatic encephalopathy and initiation of potential registrational Phase 2b/3 clinical trial planned for second half of 2020 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.